Citation

Magliocco MA, Lozano AM, Van Saders C, Schuler KW, Gottlieb AB. J. Drugs Dermatol. 2007; 6(4): 424-427.

Affiliation

Division of Clinical Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA. maglioma@umdnj.edu

Copyright

(Copyright © 2007, Physicians Continuing Education Corporation)

DOI

unavailable

PMID

17668540

Abstract

Eleven patients with well-controlled psoriasis on cyclosporine (Physician's Global Assessment [PGA] of "mild" or better) participated in an open-label study that evaluated a strategy for transition to alefacept. Using this transition strategy, 7 of 11 patients (64%) maintained PGA scores. Quality of life improved or was maintained in all patients. Adverse events and reductions in CD4+ T cell counts were consistent with those seen during alefacept monotherapy.

Language: en